Log in to search using one of your social media accounts:

 

Spironolactone Helpful in Acute Central Serous Chorioretinopathy Spironolactone Helpful in Acute Central Serous Chorioretinopathy
For patients with acute central serous chorioretinopathy (CSC), oral spironolactone is more effective than observation and absorbs subretinal fluid (SRF) faster, a randomized controlled trial from China suggests.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - November 21, 2017 Category: Pathology Tags: Pathology & Lab Medicine News Source Type: news

Oral contraceptive plus spironolactone safely addresses androgen excess in PCOS
PCOS women treated with a combination oral contraceptive with spironolactone were not at increased risk for metabolic or cardiovascular complications, according to findings published in theEuropean Journal of Endocrinology.Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - September 18, 2017 Category: Endocrinology Source Type: news

Carospir (spironolactone) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 16, 2017 Category: Drugs & Pharmacology Source Type: news

CMP Pharma, Inc. Announces FDA Approval of CaroSpir (spironolactone) Oral Suspension
Farmville, NC. August 7, 2017 – CMP Pharma today announced that the US Food and Drug Administration (FDA) has granted final approval of the company’s New Drug Application (NDA) for CaroSpir (Spironolactone Oral Suspension, 25 mg/5mL), the first... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 7, 2017 Category: Drugs & Pharmacology Source Type: news

Spironolactone Tablets (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - July 27, 2017 Category: Drugs & Pharmacology Source Type: news

Spironolactone Promising in Duchenne Muscular Dystrophy Spironolactone Promising in Duchenne Muscular Dystrophy
Preliminary results from a study of spironolactone in Duchenne muscular dystrophy suggest that the drug is safe in this patient group and may preserve left ventricular function.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - March 24, 2017 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Aldactazide (Spironolactone and Hydrochlorothiazide) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 8, 2017 Category: Drugs & Pharmacology Source Type: news

After TOPCAT: What to Do in HF With Preserved EF After TOPCAT: What to Do in HF With Preserved EF
The results of the TOPCAT trial of spironolactone for heart failure with preserved ejection fraction showed little advantage over placebo. So where does that leave clinical management?European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 27, 2016 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

What are Potential Health Problems Associated with Polycystic Ovary Syndrome?
DiscussionPolycystic ovary syndrome (PCOS) affects 6-8% of reproductive-age women making it the most common endocrinopathy in this age group. There is no consensus on the specific diagnostic criteria for PCOS in adolescents as many of the characteristics overlap with normal adolescent physiology. However, patients should have evidence of hyperandrogenism, oligo- or amenorrhea, and potentially polycystic ovaries. PCOS has a genetic component although a specific gene has not been identified. Incidence of PCOS is 20-40% for a woman with a family history. Hyperandrogenism Androgen levels change during puberty therefore actual ...
Source: PediatricEducation.org - December 5, 2016 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

No Added Value to Spironolactone in Acute HF: ATHENA-HF No Added Value to Spironolactone in Acute HF: ATHENA-HF
"It was a totally neutral trial," maybe because it looked at the wrong end points or because the role of diuretic resistance in such patients is misunderstood, according to some.Heartwire from Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 30, 2016 Category: Consumer Health News Tags: Cardiology News Source Type: news

Aldactone (spironolactone)
Title: Aldactone (spironolactone)Category: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 9/23/2016 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - September 23, 2016 Category: Cardiology Source Type: news

Aldactone (Spironolactone) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 8, 2016 Category: Drugs & Pharmacology Source Type: news

Mixed Results for Beet-Juice Effects on Arterial Function, Heart StructureMixed Results for Beet-Juice Effects on Arterial Function, Heart Structure
A small study showed signs that consuming inorganic nitrates in beetroot juice, with or without spironolactone, may improve cardiac remodeling. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 22, 2016 Category: Cardiology Tags: Cardiology News Source Type: news

Spironolactone in Patients With HF With Preserved EFSpironolactone in Patients With HF With Preserved EF
Does the efficacy of spironolactone in heart failure with preserved ejection fraction vary by LVEF amount? European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 22, 2016 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Hidden in plain sight: Well-known drug could yield new treatment for herpes viruses
(University of Utah Health Sciences) In a search for new antiviral drugs, University of Utah scientists found that a common heart failure medicine, spironolactone, has an unexpected ability to block Epstein Barr virus (EBV). The drug blocks a key step in viral infection common to all herpesviruses, revealing that it could be developed into a new class of drug to treat infections caused by herpesviruses including herpes, shingles, and mono. The research was published in PNAS. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 14, 2016 Category: Infectious Diseases Source Type: news

The Biggest Medical Stories You May Have Missed In 2015
SPECIAL FROM Next Avenue By Craig Bowron As we head into the New Year, let’s take a look back and see what lessons we should have learned from medical science in 2015. The New England Journal of Medicine’s publication Journal Watch provides physicians and other health care providers with expert analysis of the most recent medical research. Below is a brief synopsis of what the Journal Watch editors felt were the most important stories in general medicine for the year 2015. While you likely heard about a couple, others probably escaped your radar. Getting Aggressive with Strokes We’re familiar with the id...
Source: Science - The Huffington Post - January 15, 2016 Category: Science Source Type: news

What Women Can Do About Hair Loss
SPECIAL FROM Next Avenue By Sheryl Kraft Everyone loses hair. In fact, it’s normal to lose between 50 and 100 hairs a day, according to the American Academy of Dermatology. But what if it seems like there’s significantly more loss than that? “Once you exceed that, you’re losing it at an abnormal rate,” says Dr. David J. Wong, clinical associate professor of dermatology at Stanford University. Contrary to popular notion, hair loss is not just a condition that men face: up to 40 percent of women in America also experience it. No ‘Bald Is Beautiful’ for Women Bruce Willis, Patric...
Source: Healthy Living - The Huffington Post - October 20, 2015 Category: Consumer Health News Source Type: news

Spironolactone Effective for Resistant Hypertension (FREE)
By Kelly Young Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD Spironolactone is an effective add-on treatment for resistant hypertension, according to a Lancet study.Researchers studied over 300 people with a seated clinic systolic … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 22, 2015 Category: Primary Care Source Type: news

Persistent high blood pressure could be cured by Spironolactone
Spironolactone was first used in 1959 as a water pill to treat fluid retention - but a new British Heart Foundation study found it also works in three out of five patients whose blood pressure is out of control. (Source: the Mail online | Health)
Source: the Mail online | Health - September 2, 2015 Category: Consumer Health News Source Type: news

Spironolactone Effectively Lowers BP in Resistant HypertensionSpironolactone Effectively Lowers BP in Resistant Hypertension
Patients with resistant hypertension, those taking three drugs at maximally tolerated doses but still not at goal, should not be called "resistant" until they have tried spironolactone, according to PATHWAY2 researchers. Heartwire from Medscape (Source: theHeart.org)
Source: theHeart.org - August 31, 2015 Category: Cardiology Tags: Cardiology News Source Type: news

Spironolactone: The 'Other' Hormonal Acne Therapy
(MedPage Today) -- Expert: drug is effective and its safety issues can be managed (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - August 29, 2015 Category: Dermatology Source Type: news

Blood test for patients on acne medication deemed unnecessary
For young, healthy women taking spironolactone to treat hormonal acne, frequent office visits and blood draws are an unnecessary health care expense, researchers report. For the approximately 1,000 patients studied, blood tests to monitor potassium levels did not change the course of treatment, but the tests cumulatively totaled up to $80,000. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 23, 2015 Category: Science Source Type: news

Young Women Taking Spironolactone for Acne Don't Have Increased Rate of Hyperkalemia (FREE)
By Kelly Young Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH Regular potassium monitoring may not be required in young women prescribed spironolactone for acne, according to a study in JAMA Dermatology that was presented at the … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - March 23, 2015 Category: Primary Care Source Type: news

No increased rate of hyperkalemia in healthy women taking spironolactone for acne
Young women taking spironolactone for hormonally mediated acne do not need to be monitored for hyperkalemia, say the authors of a study that showed no significant increase in the risk of the condition. The retrospective study in 974 otherwise healthy women taking spironolactone found the rate of... (Source: Skin and Allergy News)
Source: Skin and Allergy News - March 22, 2015 Category: Dermatology Tags: CME-candidate SAN Acne & Rosacea SAN Journals SAN Clinical News SAN News IMN Journals FPN Journals Source Type: news

Blood test for patients on acne medication deemed unnecessary
(Brigham and Women's Hospital) A new study by researchers at Brigham and Women's Hospital has found that for young, healthy women taking spironolactone to treat hormonal acne, frequent office visits and blood draws are an unnecessary health care expense. For the approximately 1,000 patients studied, blood tests to monitor potassium levels did not change the course of treatment, but the tests cumulatively totaled up to $80,000. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 22, 2015 Category: Global & Universal Source Type: news

Blood Test for Patients on Acne Medication Deemed Unnecessary
For young, healthy women taking spironolactone, potassium monitoring may be an unnecessary expense. (Source: BWH for Journalists)
Source: BWH for Journalists - March 22, 2015 Category: Research Source Type: news

Blood Test for Patients on Acne Medication Deemed Unnecessary
For young, healthy women taking spironolactone, potassium monitoring may be an unnecessary expense. (Source: BWH News)
Source: BWH News - March 22, 2015 Category: Hospital Management Source Type: news

Antibiotic, Spironolactone Combo Ups Sudden Death in Elderly Antibiotic, Spironolactone Combo Ups Sudden Death in Elderly
When combined with spironolactone, a diuretic, trimethoprim-sulfamethoxazole is riskier than other antibiotics in people older than 65 years. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 3, 2015 Category: Consumer Health News Tags: Internal Medicine News Source Type: news

Commonly used antibiotics with diuretic can double risk of sudden death in older patients
The combination of the commonly prescribed antibiotic trimethoprim-sulfamethoxazole with the diuretic spironolactone, widely used for heart failure, more than doubles the risk of death for older patients, reports a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 2, 2015 Category: Science Source Type: news

Certain Heart Drug, Antibiotic Combo Might Be Fatal for Seniors
Doctors should not prescribe spironolactone with trimethoprim-sulfamethoxazole, study saysSource: HealthDay Related MedlinePlus Pages: Drug Reactions, Medicines, Seniors' Health (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - February 2, 2015 Category: Consumer Health News Source Type: news

Effect of Mineralocorticoid Receptor Blockade in T2DEffect of Mineralocorticoid Receptor Blockade in T2D
Does spironolactone prevent heart disease in patients with type 2 diabetes? Diabetes (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 27, 2015 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

7 Reasons Women Lose Their Hair -- And 7 Treatments
Your ponytail is shrinking...or your part's getting wider...or there's more hair in the shower drain. Take heart -- you're not alone. According to New York City dermatologist Neil Sadick, MD, up to 80 percent of women will have some hair thinning in their lifetime, even if only temporarily. It's normal to shed 50 to 100 hairs a day, says NYC dermatologist Doris Day, MD. If you're losing more than that, a doctor's visit is in order. Here are some common causes and treatments. Cause: Genetics (the most likely culprit) Treatment: Minoxidil, the only topical ingredient that's FDA approved to regrow hair in women. Rogaine ha...
Source: Healthy Living - The Huffington Post - January 26, 2015 Category: Consumer Health News Source Type: news

Is Spironolactone a 'Savior' for Hemodialysis Patients?Is Spironolactone a 'Savior' for Hemodialysis Patients?
A new study found that spironolactone significantly reduced the risk for cardiovascular and cerebrovascular morbidity and death in hemodialysis patients, reports Dr Jeffrey Berns. Medscape Nephrology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 22, 2014 Category: Consumer Health News Tags: Nephrology Commentary Source Type: news

TOPCAT Analysis: Spironolactone Benefits HFPEF in Americas TOPCAT Analysis: Spironolactone Benefits HFPEF in Americas
A new post hoc analysis questions whether many patients entered into the trial in Russia and Georgia actually had heart failure. Heartwire (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 26, 2014 Category: Cardiology Tags: Cardiology News Source Type: news

As Used, Spironolactone Doesn't Cut 30-Day HF ReadmissionsAs Used, Spironolactone Doesn't Cut 30-Day HF Readmissions
It's probably a reflection of a long-recognized problem, say researchers; patients in clinical practice just aren't a lot like those in clinical trials. Heartwire (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 15, 2014 Category: Cardiology Tags: Cardiology News Source Type: news

spironolactone, Aldactone
Title: spironolactone, AldactoneCategory: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 8/6/2014 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - August 6, 2014 Category: Cardiology Source Type: news

Spironolactone in Heart Failure? Yes, and Here's WhySpironolactone in Heart Failure? Yes, and Here's Why
Dr. Piña reviews a subgroup analysis from the TOPCAT trial, and explains why she thinks spironolactone has a role in many patients with heart failure. theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 14, 2014 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

Hyperkalemia Evident with Spironolactone in Resistant HTNHyperkalemia Evident with Spironolactone in Resistant HTN
A small study finds that 8% of resistant-hypertension patients treated with spironolactone developed hyperkalemia, including one who presented to the emergency department. Researchers advise doctors to monitor potassium levels when using the drug. Heartwire (Source: Medscape Nephrology Headlines)
Source: Medscape Nephrology Headlines - May 20, 2014 Category: Urology & Nephrology Tags: Cardiology News Source Type: news

Clinicians urged to consider spironolactone in HFPEF despite TOPCAT results
Clinicians have been urged to consider using spironolactone in their patients with heart failure and preserved ejection fraction (HFPEF) after a post-hoc analysis of the TOPCAT trial showed benefit in patients from the Americas. TOPCAT randomized 3445 patients with HFPEF to receive spironolactone, a mineralocorticoid receptor antagonist, at a dose of 15-45mg per day or placebo on top of usual care. Patients were recruited from 270 medical centres in 6 countries. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 18, 2014 Category: Science Source Type: news

Clinicians urged to consider spironolactone in HFPEF despite TOPCAT results
(European Society of Cardiology) Clinicians have been urged to consider using spironolactone in their patients with heart failure and preserved ejection fraction after a post-hoc analysis of the TOPCAT trial showed benefit in patients from the Americas.The research was presented today at the Heart Failure Congress 2014 in Athens, Greece. The Congress is the main annual meeting of the Heart Failure Association of the European Society of Cardiology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 18, 2014 Category: Global & Universal Source Type: news

Clinicians urged to consider spironolactone in HFPEF despite TOPCAT results
Clinicians have been urged to consider using spironolactone in their patients with heart failure and preserved ejection fraction (HFPEF) after a post-hoc analysis of the TOPCAT trial showed benefit in patients from the Americas.  Professor Bertram Pitt said: “We’ve had many studies showing that ACE inhibitors, angiotensin receptor blockers, beta blockers and mineralocorticoid receptor blockers reduce mortality and hospitalisations in patients with heart failure and reduced ejection fraction (HFREF). But no studies have found a benefit of these medications in HFPEF patients.” ...
Source: ESC News and Press - May 14, 2014 Category: Cardiology Source Type: news

TOPCAT reveals regional differences in spironolactone effectiveness for HFpEF
Adding spironolactone to existing treatments does not significantly reduce the composite primary outcome in patients with HF and preserved ejection fraction (HFpEF), reported the phase 3 TOPCAT study. Topics: Heart Failure (HF) (Source: ESC News and Press)
Source: ESC News and Press - April 23, 2014 Category: Cardiology Source Type: news

PodMed: A Medical News Roundup From Johns Hopkins (with audio)
(MedPage Today) -- This week's topics include new treatments for hepatitis C, paternal obesity and autism risk, aspirin and preeclampsia, and spironolactone for one form of congestive heart failure. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 11, 2014 Category: Cardiology Source Type: news

TOPCAT in Print, With Quirks: Aldo-Blocker Misses in HFPEFTOPCAT in Print, With Quirks: Aldo-Blocker Misses in HFPEF
Spironolactone didn't show a primary-end-point gain in preserved-ejection-fraction heart failure. But there were glimmers of possible benefit along with a controversy about the trial's design. Heartwire (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 10, 2014 Category: Cardiology Tags: Cardiology News Source Type: news

Does Spironolactone Benefit Patients with HF and Preserved Systolic Function? (FREE)
By Harlan M. Krumholz, MD, SM Spironolactone showed no significant advantage over placebo among patients with heart failure and preserved systolic function in a New England Journal of Medicine study, but the case may not be closed.Some 3500 adults with symptomatic heart failure and a left … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - April 10, 2014 Category: Primary Care Source Type: news

TOPCAT Study Shows Spironolactone Did Not Reduce Primary Outcome, but Did Reduce Hospitalizations for Heart Failure
Spironolactone did not significantly reduce primary endpoint (Source: BWH News)
Source: BWH News - April 10, 2014 Category: Hospital Management Source Type: news

TOPCAT Study Shows Spironolactone Did Not Reduce Primary Outcome, but Did Reduce Hospitalizations for Heart Failure
Spironolactone did not significantly reduce primary endpoint (Source: BWH for Journalists)
Source: BWH for Journalists - April 10, 2014 Category: Research Source Type: news

Spironolactone May Benefit Some HF Patients (CME/CE)
(MedPage Today) -- The TOPCAT trial of spironolactone for patients with heart failure and a preserved ejection fraction failed to meet its primary endpoint, but showed a modest reduction in heart failure hospitalizations with the drug, final results affirmed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 9, 2014 Category: Cardiology Source Type: news

Troubled NHLBI TOPCAT Trial Disappoints
Although a significant portion of people with heart failure have preserved ejection fraction, none of the proven heart failure therapies has been shown to be beneficial in this important and growing heart failure subpopulation. Now a new NHLBI-funded study has failed to find a benefit in this group for spironolactone, which is a cornerstone of therapy for heart failure patients with reduced ejection fraction. But trial investigators and heart failure experts believe it is too early to dismiss hope that spironolactone and other aldosterone antagonists-- including Pfizer's Inspra (eplerenone)-- may eventually be found to wor...
Source: Forbes.com Healthcare News - April 9, 2014 Category: Pharmaceuticals Authors: Larry Husten Source Type: news